Conexiant
Login
  • Corneal Physician
  • Glaucoma Physician
  • New Retinal Physician
  • Ophthalmology Management
  • Ophthalmic Professional
  • Presbyopia Physician
  • Retinal Physician
The Ophthalmologist
  • Explore

    Explore

    • Latest
    • Insights
    • Case Studies
    • Opinion & Personal Narratives
    • Research & Innovations
    • Product Profiles

    Featured Topics

    • Anterior Segment
    • Glaucoma
    • Retina

    Issues

    • Latest Issue
    • Archive
  • Subspecialties
    • Cataract
    • Cornea
    • Glaucoma
    • Neuro-ophthalmology
    • Oculoplastics
    • Pediatric
    • Retina
  • Business

    Business & Profession

    • Professional Development
    • Business and Entrepreneurship
    • Practice Management
    • Health Economics & Policy
  • Training & Education

    Career Development

    • Professional Development
    • Career Pathways

    Events

    • Webinars
    • Live Events
  • Events
    • Live Events
    • Webinars
  • Community

    People & Profiles

    • Power List
    • Voices in the Community
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
Subscribe
Subscribe

False

Advertisement
The Ophthalmologist / Power List / 2025 / Honorees / Retina / Mariya Moosajee

Mariya Moosajee

Professor of Molecular Ophthalmology, Consultant Ophthalmologist and Head of Genetics at Moorfields Eye Hospital NHS Foundation Trust, UCL Institute of Ophthalmology and The Francis Crick Institute, London, UK

  • Profile

About Mariya Moosajee

What is the most exciting thing happening in retina right now?

I specialize in inherited eye diseases and despite there only being one approved retinal gene therapy, and several failed clinical trials, I am still inspired by the growing number of genetic therapeutic approaches under development. The technologies of gene editing, antisense oligonucleotides, mRNA/siRNA therapy, non-viral DNA plasmid vectors, the use of lipid nanoparticles, small molecule drugs, and the dual AAV approach for larger genes, all hold great promise. I am heartened to see gene therapy being developed for age-related macular degeneration (AMD), with potential applications for other common conditions, such as myopia, in the future.

Make a bold prediction for the future of retina treatment.

Not exactly a prediction, but a wish for an affordable and translatable genetic treatment for the majority of patients with inherited retinal diseases. One which is safe and effective, for example, where we can swap the coding sequence of a gene into a cassette and prescribe the appropriate gene therapy that will help preserve sight. It’s idealistic, and in reality, will be challenging.

What advice would you give to your younger self?

I think entering any subspeciality can be overwhelming. Each has grown and evolved through the remarkable work of great academic and clinical ophthalmologists. It can be hard to see your place in a large crowd, or visualize your achievements being as successful as the pioneers. But we must acknowledge that it is a very different time, with improved levels of knowledge and access to unbelievable technology. Many conditions do not have effective treatments, and there is still much to learn about their pathophysiology. Every small discovery cumulatively adds to the advancement of the field you are working in. So just keep taking forward steps, undertake research, add to the evidence-base, and contribute your clinical viewpoint so ophthalmology keeps advancing for the benefit of patients.

Explore More in Ophthalmology

Dive deeper into the world of Ophthalmology. Explore the latest articles, case studies, expert insights, and groundbreaking research.

Newsletters

Receive the latest Ophthalmology news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

False

Advertisement

False

Advertisement

False

Advertisement
The Ophthalmologist
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.

Disclaimer

The Ophthalmologist website is intended solely for the eyes of healthcare professionals. Please confirm below: